Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab 3 vs 1 Dose for Myopic CNV
NCT01716026Phase 3Completed
- Start
- Oct 2012
- Primary completion
- Apr 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of bevacizumab in choroidal neovascularization (CNV). Started Oct 2012; status: completed.
02
Drugs
bevacizumab
03
Conditions
choroidal neovascularization (CNV)
Beyond the preview
Go deeper on NCT01716026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01716026.